Search Results - "PARP inhibitor"

Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events by Karen A. Monuszko, Laura J. Fish, Dorinda Sparacio, Christina Lizaso, Kathryn Burn, Natalie E. Wickenheisser, Larissa A. Meyer, Shelby D. Reed, Brittany A. Davidson, Laura J. Havrilesky

Connect to this object online.

Site-agnostic PARP-inhibitor maintenance therapy of advanced stage BRCA2-mutated gastric-type endocervical adenocarcinoma: A case report by Lauren Jill Tostrud, Sahana Somasegar, Malte Renz

Connect to this object online.

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies by Attwa MW, Kadi AA, Abdelhameed AS, Alhazmi HA

Connect to this object online.

Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials by Liu Y, Meng J, Wang G

Connect to this object online.

Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer? by Yiu-Tai Li, Peng-Hui Wang

Connect to this object online.

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data by Quanfeng Zhao, Pan Ma, Peishu Fu, Jiayu Wang, Jiayu Wang, Kejing Wang, Kejing Wang, Lin Chen, Lin Chen, Yang Yang, Yang Yang

Connect to this object online.

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation by Zhong L, Yin R, Song L

Connect to this object online.

Metastatic squamous cell carcinoma arising from mature teratoma of the ovary: Description of multi-modality treatment including incorporation of adjuvant immunotherapy and maintenance PARP inhibitor therapy by Esther Peluso, Wesleigh Fowler Edwards, Jo Marie Tran Janco

Connect to this object online.

Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis by Min Tang, Yue Wang, Pulin Li, Rui Han, Ran Wang

Connect to this object online.

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials by Yan Wei, Li He, Tao Liu, Tao Guo, Cong Xie, Jigang Jia, Yonghong Lin, Jiang Liu, Jiayin Fan

Connect to this object online.

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring by Giovanni Canil, Marco Orleni, Bianca Posocco, Sara Gagno, Alessia Bignucolo, Marcella Montico, Rossana Roncato, Serena Corsetti, Michele Bartoletti, Giuseppe Toffoli

Connect to this object online.

Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement by Ling Yu, Jietao Lin, Hanhan Li, Lingling Sun, Shubo Wang, Yaoxu Chen, Hanrui Chen, Lizhu Lin

Connect to this object online.

PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms by Trevanne Matthews Hew MD, Lara Zuberi MD

Connect to this object online.

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

Subjects: “…PARP inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Targeted Cancer Therapy and Mechanisms of Resistance

Subjects: “…PARP inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Integrating Clinical and Translational Research Networks-Building Team Medicine

Subjects: “…PARP inhibitor…”
DOAB: download the publication
DOAB: description of the publication

Precision Medicine in Solid Tumors

Subjects: “…PARP inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Plasma in Cancer Treatment

Subjects: “…PARP-inhibitor…”
DOAB: download the publication
DOAB: description of the publication

Anticancer Agents Design, Synthesis and Evaluation

Subjects: “…PARP inhibitor…”
DOAB: download the publication
DOAB: description of the publication

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy by Nan Zhang, Hong Zheng, Yunong Gao, Tong Shu, Hongguo Wang, Yan Cai

Connect to this object online.